⚡ Flash Summary
LIVEN Pharma Limited has announced the dispatch of letters of rights, CDC intimation letters, and Schedule 1 (Offer Document) to its shareholders as of December 1, 2025. This pertains to the company’s right issue offering, allowing existing shareholders to purchase additional shares. The letters of rights have been credited to CDS accounts on November 28, 2025, with a ratio of 21.496% ordinary shares for every 100 shares held as of November 26, 2025. Key dates for trading, subscription, and credit of securities are outlined, requiring shareholders to take action within specified timelines to participate in the offering.
📌 Key Takeaways
- ✉️ Letters of rights dispatched to shareholders on December 1, 2025.
- 📜 CDC intimation letters and Schedule 1 (Offer Document) also dispatched.
- 🗓️ Unpaid rights credited to CDS accounts on November 28, 2025.
- ⚖️ Rights ratio: 21.496% ordinary shares for every 100 shares held.
- 🗓️ Commencement of trading of unpaid rights: December 1, 2025.
- 🗓️ Last date of trading of unpaid rights: December 15, 2025.
- 🗓️ Subscription of right offer start date: December 1, 2025.
- 🗓️ Last date of subscription of right offer: December 22, 2025.
- 🗓️ Date of credit of right securities into CDS: January 6, 2026.
- 🏦 Meezan Bank Limited is the banker for the right issue.
- 📝 CDS account holders must request Right Subscription Request in writing.
- 💰 Payment can be made by cash, cheque, demand draft, or pay order.
- 💻 Online payment option available through 1Link for rights subscription.
- 📑 Physical shareholders must deposit unpaid rights into CDS by December 15, 2025.
- ❌ Paid Right Subscription Requests cannot be traded or transferred.
🎯 Investment Thesis
HOLD. The right issue presents both opportunities and risks. Existing shareholders should carefully evaluate the terms of the offering and their own financial situation before deciding whether to subscribe. Without more detailed financial information, a definitive BUY or SELL recommendation cannot be made. A HOLD rating reflects the need for further assessment pending the outcome of the right issue and subsequent company performance. Price target is contingent on successful capital raise and subsequent deployment of funds.
Disclaimer: AI-generated analysis. Not financial advice.